Literature DB >> 11080200

Loss of cannabinoid-stimulated guanosine 5'-O-(3-[(35)S]Thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats.

T Rubino1, D Viganò, B Costa, M Colleoni, D Parolaro.   

Abstract

The endogenous cannabinoid anandamide has been reported to produce well-defined behavioral tolerance, but studies on the possible mechanisms underlying this process are few and often contradictory. The present study was designed to survey the cellular events involved in anandamide tolerance, in terms of the effects on receptor number, coupling with G proteins, and activation of the cyclic AMP (cAMP) cascade. Chronic treatment of rats with anandamide (20 mg/kg i.p. for 15 days) resulted in behavioral tolerance without any change in cannabinoid receptor binding in the brain regions studied (striatum, cortex, hippocampus, and cerebellum), suggesting that receptor down-regulation was not involved in the development of anandamide behavioral tolerance. In contrast, prolonged exposure to anandamide significantly reduced agonist-stimulated guanosine 5'-O:-(3-[(35)S]thiotriphosphate) binding in the same areas, with losses of >50%, suggesting that receptor desensitization may be part of the molecular mechanism underlying this tolerance. Finally, concerning the cAMP cascade-the most well-known intracellular signaling pathways activated by CB(1) receptors-in the brain regions from rats tolerant to anandamide, we found no alteration in cAMP levels or in protein kinase A activity. We propose that anandamide, unlike Delta(9)-tetrahydrocannabinol and other cannabinoids, does not alter the receptor system at multiple levels but that desensitization of the CB(1) receptor might account for behavioral tolerance to the drug.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11080200     DOI: 10.1046/j.1471-4159.2000.0752478.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  11 in total

Review 1.  The endocannabinoid system as a target for the treatment of cannabis dependence.

Authors:  Jason R Clapper; Regina A Mangieri; Daniele Piomelli
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

2.  Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in fatty acid amide hydrolase wild-type and knockout mice.

Authors:  Joel E Schlosburg; Steven G Kinsey; Bogna Ignatowska-Jankowska; Divya Ramesh; Rehab A Abdullah; Qing Tao; Lamont Booker; Jonathan Z Long; Dana E Selley; Benjamin F Cravatt; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2014-05-21       Impact factor: 4.030

3.  FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.

Authors:  Katherine W Falenski; Andrew J Thorpe; Joel E Schlosburg; Benjamin F Cravatt; Rehab A Abdullah; Tricia H Smith; Dana E Selley; Aron H Lichtman; Laura J Sim-Selley
Journal:  Neuropsychopharmacology       Date:  2010-03-31       Impact factor: 7.853

4.  Ovarian hormones and chronic administration during adolescence modify the discriminative stimulus effects of delta-9-tetrahydrocannabinol (Δ⁹-THC) in adult female rats.

Authors:  Peter J Winsauer; Catalin M Filipeanu; Evangeline M Bailey; Jerielle L Hulst; Jessie L Sutton
Journal:  Pharmacol Biochem Behav       Date:  2012-06-15       Impact factor: 3.533

Review 5.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Activation of G-proteins in brain by endogenous and exogenous cannabinoids.

Authors:  Steven R Childers
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

7.  Chronic administration during early adulthood does not alter the hormonally-dependent disruptive effects of delta-9-tetrahydrocannabinol (Δ9-THC) on complex behavior in female rats.

Authors:  Peter J Winsauer; Jessie L Sutton
Journal:  Pharmacol Biochem Behav       Date:  2013-12-18       Impact factor: 3.533

8.  Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats.

Authors:  Jenny L Wiley; Seth H Kendler; James J Burston; Daniel R Howard; Dana E Selley; Laura J Sim-Selley
Journal:  Neuropharmacology       Date:  2008-07-30       Impact factor: 5.250

9.  Changes in the expression of G protein-coupled receptor kinases and beta-arrestins in mouse brain during cannabinoid tolerance: a role for RAS-ERK cascade.

Authors:  Tiziana Rubino; Daniela Viganò; Fabrizio Premoli; Chiara Castiglioni; Silvia Bianchessi; Renata Zippel; Daniela Parolaro
Journal:  Mol Neurobiol       Date:  2006-06       Impact factor: 5.682

10.  Hormonal status and age differentially affect tolerance to the disruptive effects of delta-9-tetrahydrocannabinol (Δ(9)-THC) on learning in female rats.

Authors:  Peter J Winsauer; Catalin M Filipeanu; Peter F Weed; Jessie L Sutton
Journal:  Front Pharmacol       Date:  2015-07-02       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.